GLP‑1 Drugs and Employer Health Plans: What Plan Sponsors Need to Know

Below is an informational overview but is not legal advice and employers should always consult their own counsel and advisors before making plan changes.

Employers are being asked more and more about GLP‑1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound; not just by employees, but by finance teams, HR, and leadership looking at rising health plan costs. GLP‑1s are changing the landscape of diabetes and obesity treatment, and they are also raising important compliance and plan‑design questions for employers and plan sponsors.

What Are GLP‑1 Drugs and Why Are Employees Asking About Them?

GLP‑1 receptor agonists (such as semaglutide and tirzepatide) work by mimicking a natural hormone that helps control blood sugar, slows digestion, and reduces appetite. They were originally developed to treat Type 2 diabetes, but several of these medications are now widely prescribed for weight loss and long‑term weight management.

A few key points employers should know:

• GLP‑1 brands you hear about most often include Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide).
• These medications can lead to meaningful weight loss and improved cardiometabolic health when combined with diet and exercise.
• Demand has surged; national surveys show a growing share of adults have used or are using GLP‑1s for weight loss or chronic conditions.

For employers and plan sponsors, that demand quickly turns into questions: “Is it covered?” “For what conditions?” and “For how long?”

What Is Actually FDA‑Approved?

It is important to understand what GLP‑1s are officially approved to treat, because that often shapes how plans choose to cover them.

• Certain GLP‑1 drugs (like Wegovy and Zepbound) are FDA‑approved for weight loss or long‑term weight management in adults with obesity, or adults who are overweight with at least one weight‑related condition, when used along with diet and exercise.
• Wegovy is also approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have cardiovascular disease and obesity or are overweight.
• Zepbound has an additional approval to treat moderate to severe obstructive sleep apnea in adults with obesity.
• Other GLP‑1s, including Ozempic and Mounjaro, are approved for Type 2 diabetes but are frequently prescribed “off‑label” for weight loss.

For benefit plans, the distinction between “approved for diabetes” and “approved for weight management or other conditions” matters when designing coverage rules and communicating with employees.

Are Employers Required to Cover GLP‑1 Drugs?

At the federal level, there is currently no blanket requirement that employer‑sponsored health plans cover GLP‑1 drugs for either diabetes or weight loss. In other words, coverage is largely a plan design decision, subject to general federal benefit mandates and any applicable state insurance rules for fully insured plans.

A few compliance‑related facts:

• Self‑funded employer plans generally have broad flexibility to decide whether and how to cover GLP‑1s, within the overall framework of ERISA, the ACA, HIPAA, and mental health parity rules.
• Fully insured plans must comply with the insurance mandates of the state where the policy is issued, but at this time state‑level GLP‑1 coverage mandates are still very limited.
• As of 2025, North Dakota stands out: its ACA essential health benefits benchmark requires coverage of GLP‑1/GIP drugs as therapy for prevention of diabetes and treatment of insulin resistance, metabolic syndrome, or morbid obesity in individual and small‑group plans, excluding grandfathered and large‑group coverage.

For NARFA members and other employers, this means GLP‑1 coverage is not “one size fits all.” It is a strategic choice that needs to balance clinical value, cost, and compliance.

How Are Employers Handling GLP‑1 Coverage Today?

Survey data show that many large employers have moved to cover GLP‑1s in some form, but not without challenges.

• Nearly 20% of employers with 200 or more employees report that their largest health plan covers GLP‑1s used primarily for weight loss.
• Among very large employers (5,000+ employees), reported coverage rates climb to as high as 43%.
• Employers that add coverage often see higher‑than‑expected utilization and a significant impact on prescription drug spending, which has led some to scale back coverage or tighten requirements.

In practice, many plans that do cover GLP‑1s for weight management are not offering “open‑ended” access:

• Clinical eligibility criteria (for example, BMI thresholds and documented weight‑related conditions).
• Prior authorization to confirm that criteria are met and to control inappropriate use.
• Step therapy, requiring lower‑cost alternatives or lifestyle interventions first.
• Requirements to participate in nutrition, behavioral health, or lifestyle programs as a condition of coverage.

For a self‑funded employer, these tools are often critical to balancing access with affordability.

Where Do Compliance and Nondiscrimination Come In?

This is where GLP‑1 plan decisions get more complex. While employers have flexibility, indication‑based coverage choices can raise nondiscrimination questions.

“Indication‑based” means the plan covers a drug for one diagnosis, but not for another; for example, covering GLP‑1s for diabetes, but excluding them when prescribed for obesity or addiction‑related treatment. This type of design may implicate several laws:

• The Americans with Disabilities Act (ADA), especially in cases where obesity is tied to an underlying medical condition or considered a disability.
• The Affordable Care Act’s nondiscrimination provisions, which prohibit certain forms of discrimination in health coverage.
• HIPAA nondiscrimination rules relating to eligibility and benefits.
• The Mental Health Parity and Addiction Equity Act (MHPAEA), if GLP‑1 use is tied to mental health or substance‑use treatment.
• State and local laws where weight or obesity status is a protected characteristic.

Some employees have sued insurers over GLP‑1 exclusions for obesity, arguing disability discrimination under the ACA; to date, these cases have mostly targeted carriers and have largely been unsuccessful, but they signal where the legal arguments may go next. For employers and plan sponsors, this environment reinforces the need to vet GLP‑1 coverage strategies with experienced benefits counsel.

What If a Plan Chooses Not to Cover GLP‑1s for Weight Loss?

Not every employer will choose to cover GLP‑1s for weight management, particularly in industries facing tight margins and volatile healthcare costs. Even so, there are ways to support employees within a compliant framework.

Employers might:

• Focus plan coverage on GLP‑1 use for diabetes and other FDA‑approved high‑risk indications, such as cardiovascular disease or obstructive sleep apnea, while clearly communicating those standards.
• Invest in proven lifestyle, nutrition, and disease‑management programs that address weight, cardiometabolic risk, and overall wellness.
• Strengthen consumer‑driven health strategies, including HSAs and FSAs, so that eligible prescriptions can be paid with pre‑tax dollars when IRS rules are satisfied.
• Provide clear communication about what is and is not covered, the reasons behind those decisions, and where employees can go for additional help or resources.

Tax‑advantaged accounts are not a substitute for coverage, but they can offer an additional tool for employees working with their physicians on GLP‑1 therapy, subject to eligibility and proper documentation.

Practical Next Steps for Employers and Plan Sponsors

For NARFA members and other employers looking ahead to upcoming plan years, GLP‑1 decisions should be approached strategically and collaboratively. Consider:

• Defining a clear GLP‑1 coverage philosophy: diabetes only, targeted weight‑loss coverage with guardrails, or exclusion for weight management with strong alternatives.
• Working with your TPA, PBM, and advisors to implement appropriate utilization management tools if you do offer coverage for weight loss.
• Reviewing plan language for potential nondiscrimination and parity issues, especially where coverage differs by diagnosis.
• Coordinating with legal counsel to align your approach with evolving federal and state requirements and emerging case law.

NARFA’s role is to help employers navigate these complex decisions with clear information, practical options, and a focus on long‑term sustainability of their benefit programs. As GLP‑1 utilization continues to grow, thoughtful plan design and strong communication will be essential.

Again, this article is for informational purposes only and does not constitute legal advice. Employers should consult their own legal and tax advisors before making decisions about GLP‑1 coverage or any other aspect of their health plans.